Trasylol™ / Aprotinin
| Bayer AG is removing Trasylol™ from the market completely. Compared to two less-expensive alternatives, Trasylol™ increased the risk of death by 54%. Don't hesitate any longer. If you or a loved one has suffered injury or death after being given Trasylol™ or aprotinin after heart surgery, submit your case via form or call The Law Offices of Larry H. Parker today at (800) 333-0000 for a free, no-obligation, confidential consultation. We'll Fight for You™! |
On January 26, 2006, the New England Journal of Medicine published an article on The Risk Associated with Aprotinin in Cardiac Surgery. This article studied the use of aprotinin on patients who had undergone cardiac bypass surgery and found a heightened risk of kidney failure, heart attack, heart failure, stroke, and brain disorders associated with the use of aprotinin.
| "[U]se of aprotinin was associated with a doubling in the risk of renal failure requiring dialysis among patients undergoing complex coronary-artery surgery (odds ratio, 2.59; 95 percent confidence interval, 1.36 to 4.95) or primary surgery (odds ratio, 2.34; 95 percent confidence interval, 1.27 to 4.31). Similarly, use of aprotinin in the latter group was associated with a 55 percent increase in the risk of myocardial infarction or heart failure (P<0.001) and a 181 percent increase in the risk of stroke or encephalopathy (P=0.001)." |
In February of 2008, The New England Journal of Medicine published an article about a new study on the blood-clotting drug Trasylol™. Also known generically as aprotinin, Trasylol™ was given to more than 10,000 patients at Duke University Medical Center between 1996 and 2005. 6.4% of patients that were given Trasylol™ died within 30 days of the surgery, a rate nearly 250% higher than patients who received a different bleed control drug or no treatment at all. 16% of patients who received Trasylol™ died within one year of the surgery, also about 250% higher than the other patients.
Even more troubling is that Bayer AG, the manufacturer of Trasylol™, commissioned their own study of the drug and concluded there was an increased risk of death after surgery. Bayer knew of this information as early as September 2006, but chose to withhold this information from the FDA. Bayer withdrew aprotinin from the market on November 5th, 2007. Dr. Sidney Wolfe of the Public Citizen's Health Research Group has called for criminal charges to be filed against Bayer for withholding the results of its study.
About Trasylol™ (aprotinin)
![[Trasylol Blood Transfusion]](photos/transfusion.jpg)
Trasylol™ is the brand name for the drug aprotinin. Trasylol™ is manufactured and distributed by Bayer Pharmaceuticals. The U.S. Food and Drug Administration (FDA) has approved Trasylol™ for preventative use to reduce blood loss and the need for blood transfusions in patients undergoing heart bypass surgery.
Risks Associated With Trasylol™
A study published in the New England Journal of Medicine found the following risks associated with the use of aprotinin:
- a doubling in the risk of kidney failure;
- a 55% increase in the risk of a heart attack or heart failure;
- a 181% increase in the risk of stroke or brain disorder.
The study also recommended against the continued use of aprotinin.
We Can Help
If you have been treated with Trasylol™ (aprotinin) and have suffered kidney failure, a heart attack, heart failure or a stroke, we can help. The Law Offices of Larry H. Parker has assembled a team of experienced product liability lawyers to handle your Trasylol™ case. For a free, confidential, no-obligation consultation, please fill out a form, send us an email or call us at (800) 333-0000. No recovery, no fee! Serving all of California, and now in Arizona with offices in Phoenix and Tucson. We'll Fight For You!™
Esta Larry H. Parker página web es disponible en español
(Arizona clients will be liable for expenses regardless of the outcome unless the repayment of such is contingent upon the outcome of the matter and the percentage fee will be computed before expenses are deducted from the recovery.)
* Please be advised that no attorney/client relationship will be established by website visit or submission to either FightForYou.com™ or larryhparker.com™. An attorney/client relationship can only begin when a retainer has been signed.
